An international Phase 3 study — ISLEND-1 — reported in July 2026 that a once-weekly oral regimen of islatravir and lenacapavir maintained viral suppression as effectively as standard daily therapy after 48 weeks.
Gilead and Merck announced positive topline results from two Phase 3 trials (ISLEND-1 and ISLEND-2), with the primary endpoint met at Week 48. This is the first time a weekly oral regimen has matched daily therapy in a Phase 3 setting.
Why daily pills are a problem
Modern HIV treatment works extraordinarily well. But it still requires taking a pill every single day, for life. Missed doses can lead to viral rebound. Missed doses over time can lead to drug resistance.
For many people, adherence is not about forgetting. It is about:
- The risk of someone finding the pills
- The exhaustion of a daily reminder of your status
- Feeling unwell from side effects and skipping a dose
- Travel, disruptions, and running out of supply
A weekly pill is not a cure. But it removes the daily reminder, the daily risk of discovery, and the daily adherence burden.
How islatravir-lenacapavir works
Islatravir is a nucleoside reverse transcriptase translocation inhibitor — a newer class of drug. Lenacapavir is a capsid inhibitor, the same drug now being used as a twice-yearly prevention injection. Together, they attack HIV at two different points in its replication cycle.
The combination's long half-life is what makes a weekly dose possible. Both drugs stay active in the body for days, so a single weekly pill maintains continuous suppression.
What the trials showed
Participants who switched from daily therapy to the weekly regimen maintained viral suppression at rates statistically non-inferior to those who stayed on daily therapy. That is the standard regulatory benchmark — not "better than," but "not worse than."
Safety data was comparable, with no new signals of concern.
What comes next
Phase 3 results are not approval. Both companies will now submit regulatory filings. The FDA typically takes 6–12 months to review. If approved, the earliest a weekly pill could be available in the United States is 2027.
Availability in South Africa depends on several things: WHO prequalification, pricing agreements, and provincial health department budgets. Based on the timelines for other new HIV medications, expect South Africa to have access in 2028 at the earliest.
Should you wait for a weekly pill?
No. Current daily therapy keeps you healthy and keeps your viral load undetectable. If you are doing well on your current regimen, stay on it. When the weekly option becomes available, you and your doctor can decide whether to switch.
Haven is a dating and community app built for the HIV+ community in South Africa.
Get Haven on Google Play